Last update 21 Nov 2024
EMB-09
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism OX40 inhibitors(Tumor necrosis factor receptor superfamily member 4 inhibitors), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with EMB-09一种靶向PD-L1和OX-40的双特异性抗体EMB-09在晚期或转移性实体瘤患者中的首次人体I期试验
[Translation] A first-in-human phase I trial of EMB-09, a bispecific antibody targeting PD-L1 and OX-40, in patients with advanced or metastatic solid tumors
A First-in-human, Phase I Trial of EMB-09, a Bispecific Antibody Targeting PD-L1 and OX-40 in Patients With Advanced or Metastatic Solid Tumors
100 Clinical Results associated with EMB-09
Login to view more data
100 Translational Medicine associated with EMB-09
Login to view more data
100 Patents (Medical) associated with EMB-09
Login to view more data
100 Deals associated with EMB-09
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Phase 1 | AU | 11 Jul 2022 | |
| Hepatocellular Carcinoma | Phase 1 | AU | 11 Jul 2022 | |
| Melanoma | Phase 1 | AU | 11 Jul 2022 | |
| Nasopharyngeal Carcinoma | Phase 1 | AU | 11 Jul 2022 | |
| Non-Small Cell Lung Cancer | Phase 1 | AU | 11 Jul 2022 | |
| Renal Cell Carcinoma | Phase 1 | AU | 11 Jul 2022 | |
| Small Cell Lung Cancer | Phase 1 | AU | 11 Jul 2022 | |
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | AU | 11 Jul 2022 | |
| Triple Negative Breast Cancer | Phase 1 | AU | 11 Jul 2022 | |
| Neoplasms | Phase 1 | AU | 09 Mar 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free